MedPageToday -- Patients with metastatic colorectal cancer whose tumors have a specific KRAS mutation may benefit from treatment with the monoclonal antibody cetuximab (Erbitux), according to a retrospective observational study.
MedPageToday -- Patients with metastatic colorectal cancer whose tumors have a specific KRAS mutation may benefit from treatment with the monoclonal antibody cetuximab (Erbitux), according to a retrospective observational study.
